Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


02.05.2022

1 Ann Oncol
1 Bioengineered
1 Biosens Bioelectron
3 BJUI Compass
1 BMC Cancer
1 Br J Cancer
1 Brachytherapy
1 Cancer Discov
6 Clin Genitourin Cancer
3 Curr Opin Urol
1 Diagnostics (Basel)
1 Dtsch Med Wochenschr
1 Eur J Radiol
1 Evid Based Complement Alternat Med
2 Expert Rev Anticancer Ther
1 Front Immunol
1 Front Oncol
1 Front Pharmacol
1 Front Surg
2 Genes (Basel)
1 Hinyokika Kiyo
1 Hum Pathol
1 Int J Mol Sci
1 Int J Radiat Biol
1 Int J Surg Pathol
1 J Clin Lab Anal
1 J Invest Surg
1 J Oncol
1 J Oncol Pharm Pract
1 JAMA Netw Open
1 Jpn J Clin Oncol
1 Life (Basel)
1 Med Lav
1 Mol Biol Rep
1 Mol Carcinog
1 Mol Clin Oncol
1 Neurol Sci
1 Oncotarget
1 Oxid Med Cell Longev
1 Pathol Oncol Res
3 Scand J Urol
1 Sci Rep
1 Semin Oncol
1 Urol Case Rep
1 Urol Oncol
1 Urologia
2 Virchows Arch
2 World J Surg Oncol
2 World J Urol
1 Zhejiang Da Xue Xue Bao Yi Xue Ban


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Oncol

  1. SUBBIAH V, Iannotti NO, Gutierrez M, Smith DC, et al
    FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Ann Oncol. 2022;33:522-533.
    PubMed         Abstract available


    Bioengineered

  2. GU Q, Hou W, Shi L, Zhu Z, et al
    CircMCTP2 (has-circ-0000658) facilitates the proliferation and metastasis of bladder carcinoma through modulating the miR-498/murine double minute-2 axis.
    Bioengineered. 2022;13:10734-10748.
    PubMed         Abstract available


    Biosens Bioelectron

  3. FU Y, Zhao Z, Shi Y, Xu K, et al
    Hybridization chain reaction-mediated Fe2MoO4 bimetallic nanozyme for colorimetric risk prediction of bladder cancer.
    Biosens Bioelectron. 2022;210:114272.
    PubMed         Abstract available


    BJUI Compass

  4. RUSSELL B, Haggstrom C, Holmberg L, Liedberg F, et al
    Systematic review of the association between socioeconomic status and bladder cancer survival with hospital type, comorbidities, and treatment delay as mediators.
    BJUI Compass. 2021;2:140-158.
    PubMed         Abstract available

  5. RODRIGUEZ-HOMS M, Baack Kukreja J
    Bladder cancer biomarkers: Past and future directions.
    BJUI Compass. 2021;2:7-8.
    PubMed        

  6. GROVER S, Raj S, Russell B, Mensah E, et al
    Long-term outcomes of outpatient laser ablation for recurrent non-muscle invasive bladder cancer: A retrospective cohort study.
    BJUI Compass. 2021;3:124-129.
    PubMed         Abstract available


    BMC Cancer

  7. YANG Z, Zhang X, Zhang J, Gao J, et al
    Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT
    BMC Cancer. 2022;22:462.
    PubMed         Abstract available


    Br J Cancer

  8. ZHOU Z, Zhang Z, Chen H, Bao W, et al
    SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling.
    Br J Cancer. 2022 Apr 28. pii: 10.1038/s41416-022-01794.
    PubMed         Abstract available


    Brachytherapy

  9. OZAWA Y, Yagi Y, Nakamura K, Hattori S, et al
    Secondary bladder cancer during long-term follow-up after iodine-125 permanent seed implantation for localized prostate cancer.
    Brachytherapy. 2022 Apr 20. pii: S1538-4721(22)00037.
    PubMed         Abstract available


    Cancer Discov


  10. Addition of Nintedanib to Neoadjuvant Chemotherapy Is Safe in Bladder Cancer.
    Cancer Discov. 2022 Apr 29:OF1. doi: 10.1158/2159-8290.CD-RW2022.
    PubMed         Abstract available


    Clin Genitourin Cancer

  11. LYOU Y, Rosenberg JE, Hoffman-Censits J, Quinn DI, et al
    Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma.
    Clin Genitourin Cancer. 2022;20:35-42.
    PubMed         Abstract available

  12. PATEL SH, Wang S, Metcalf MR, Gupta N, et al
    Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage.
    Clin Genitourin Cancer. 2022;20:60-68.
    PubMed         Abstract available

  13. MORI K, Katayama S, Laukhtina E, Schuettfort VM, et al
    Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma.
    Clin Genitourin Cancer. 2022;20:95.
    PubMed         Abstract available

  14. CURRAN C, Adib E, Kazakova V, Grivas P, et al
    Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.
    Clin Genitourin Cancer. 2022;20:11-16.
    PubMed         Abstract available

  15. LEITE KRM, Borges LL, Filho LR, Chade D, et al
    Histological Variants of Urothelial Carcinoma Predict No Response to Neoadjuvant Chemotherapy.
    Clin Genitourin Cancer. 2022;20:e1-e6.
    PubMed         Abstract available

  16. ALHALABI O, Hahn AW, Msaouel P, Meric-Bernstam F, et al
    Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
    Clin Genitourin Cancer. 2022;20:e16-e24.
    PubMed         Abstract available


    Curr Opin Urol

  17. HUSSEIN AA, Li Q, Guru KA
    Robot-assisted radical cystectomy: surgical technique, perioperative and oncologic outcomes.
    Curr Opin Urol. 2022;32:116-122.
    PubMed         Abstract available

  18. LONATI C, Moschini M, Simeone C, Spiess PE, et al
    Lynch syndrome in urological practice: diagnosis, therapeutic strategies, and screening for upper tract urothelial carcinoma.
    Curr Opin Urol. 2022;32:40-47.
    PubMed         Abstract available

  19. BERNDL F, Hassler MR
    Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations.
    Curr Opin Urol. 2022;32:48-53.
    PubMed         Abstract available


    Diagnostics (Basel)

  20. LEWANDOWSKA K, Lewandowska A, Baranska I, Klatt M, et al
    Severe Respiratory Failure Due to Pulmonary BCGosis in a Patient Treated for Superficial Bladder Cancer.
    Diagnostics (Basel). 2022;12.
    PubMed         Abstract available


    Dtsch Med Wochenschr

  21. METZEN M, Kowar M, Solleder G, Wilhelm K, et al
    [BCG-therapy as a rare reason for postrenal failure].
    Dtsch Med Wochenschr. 2022;147:403-406.
    PubMed         Abstract available


    Eur J Radiol

  22. LI Q, Cao B, Liu K, Sun H, et al
    Detecting the muscle invasiveness of bladder cancer: An application of diffusion kurtosis imaging and tumor contact length.
    Eur J Radiol. 2022;151:110329.
    PubMed         Abstract available


    Evid Based Complement Alternat Med

  23. TIAN YH, He YF, Tan JS, Jiang Y, et al
    The DeltaN p63 Promotes EMT and Metastasis in Bladder Cancer by the PTEN/AKT Signalling Pathway.
    Evid Based Complement Alternat Med. 2022;2022:9566055.
    PubMed         Abstract available


    Expert Rev Anticancer Ther

  24. ALEVIZAKOS M, Bellmunt J
    Adjuvant immunotherapy for muscle-invasive urothelial carcinoma of the bladder.
    Expert Rev Anticancer Ther. 2022;22:259-267.
    PubMed         Abstract available

  25. JACKSON-SPENCE F, Szabados B, Toms C, Yang YH, et al
    Avelumab in locally advanced or metastatic urothelial carcinoma.
    Expert Rev Anticancer Ther. 2022;22:135-140.
    PubMed         Abstract available


    Front Immunol

  26. ZHANG Q, Tan Y, Zhang J, Shi Y, et al
    Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer.
    Front Immunol. 2022;13:782982.
    PubMed         Abstract available


    Front Oncol

  27. ZUPPONE S, Assalini C, Minici C, Botrugno OA, et al
    A Novel RGD-4C-Saporin Conjugate Inhibits Tumor Growth in Mouse Models of Bladder Cancer.
    Front Oncol. 2022;12:846958.
    PubMed         Abstract available


    Front Pharmacol

  28. LIU CQ, Sun JX, Xu JZ, Qian XY, et al
    Metformin Use on Incidence and Oncologic Outcomes of Bladder Cancer Patients With T2DM: An Updated Meta-Analysis.
    Front Pharmacol. 2022;13:865988.
    PubMed         Abstract available


    Front Surg

  29. NIE S, Huili Y, He Y, Hu J, et al
    Identification of Bladder Cancer Subtypes Based on Necroptosis-Related Genes, Construction of a Prognostic Model.
    Front Surg. 2022;9:860857.
    PubMed         Abstract available


    Genes (Basel)

  30. QIN C, Chen ZH, Cao R, Shi MJ, et al
    Differential Expression Profiles and Bioinformatics Analysis of tRNA-Derived Small RNAs in Muscle-Invasive Bladder Cancer in a Chinese Population.
    Genes (Basel). 2022;13.
    PubMed         Abstract available

  31. DUAN L, Liu X, Luo Z, Zhang C, et al
    G-Protein Subunit Gamma 4 as a Potential Biomarker for Predicting the Response of Chemotherapy and Immunotherapy in Bladder Cancer.
    Genes (Basel). 2022;13.
    PubMed         Abstract available


    Hinyokika Kiyo

  32. KUROKAWA G, Sasaki H, Shimada H, Kasai K, et al
    [Laparoscopic Radical Cystectomy with Ileal Neobladder for Metachronous Bladder Cancer Following Laparoscopic Radical Prostatectomy : A Case Report].
    Hinyokika Kiyo. 2022;68:87-90.
    PubMed         Abstract available


    Hum Pathol

  33. CHENG M, Wang Q, Chen L, Zhao D, et al
    LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways.
    Hum Pathol. 2022;123:59-73.
    PubMed         Abstract available


    Int J Mol Sci

  34. DI MEO NA, Loizzo D, Pandolfo SD, Autorino R, et al
    Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available


    Int J Radiat Biol

  35. ITO Y, Yamamoto T, Miyai K, Take J, et al
    Ascorbic acid-2 glucoside mitigates intestinal damage during pelvic radiotherapy in a rat bladder tumor model.
    Int J Radiat Biol. 2022;98:942-957.
    PubMed         Abstract available


    Int J Surg Pathol

  36. MERTENS LS, Claps F, Mayr R, Hodgson A, et al
    The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis.
    Int J Surg Pathol. 2022 Apr 24:10668969221095173. doi: 10.1177/10668969221095173
    PubMed         Abstract available


    J Clin Lab Anal

  37. PAN X, Chen G, Hu W
    Piperlongumine increases the sensitivity of bladder cancer to cisplatin by mitochondrial ROS.
    J Clin Lab Anal. 2022 Apr 25:e24452. doi: 10.1002/jcla.24452.
    PubMed         Abstract available


    J Invest Surg

  38. PI J, Xiong Y, Liu C, Liao J, et al
    A Nomogram Model to Predict Recurrence of Non-Muscle Invasive Bladder Urothelial Carcinoma After Resection Based on Clinical Parameters and Immunohistochemical Markers.
    J Invest Surg. 2022;35:1186-1194.
    PubMed         Abstract available


    J Oncol

  39. LI J, Liu M, Sun P, Zhao W, et al
    Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory Factors and Immune Function.
    J Oncol. 2022;2022:9347218.
    PubMed         Abstract available


    J Oncol Pharm Pract

  40. NELSON D, Kodsi M, Cockrell D, Morgan J, et al
    Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab.
    J Oncol Pharm Pract. 2022;28:979-982.
    PubMed         Abstract available


    JAMA Netw Open

  41. MORTEZAVI A, Crippa A, Kotopouli MI, Akre O, et al
    Association of Open vs Robot-Assisted Radical Cystectomy With Mortality and Perioperative Outcomes Among Patients With Bladder Cancer in Sweden.
    JAMA Netw Open. 2022;5:e228959.
    PubMed         Abstract available


    Jpn J Clin Oncol

  42. MATSUSHITA Y, Kawakami A, Sato R, Watanabe K, et al
    Significant impact of a history of prior or concomitant upper urinary tract cancer on the recurrence and progression of non-muscle invasive bladder cancer.
    Jpn J Clin Oncol. 2022 Apr 23. pii: 6573315. doi: 10.1093.
    PubMed         Abstract available


    Life (Basel)

  43. MAJ M, Kazmierski L, Balik K, Kowalska K, et al
    Bladder Cancer Cells Exert Pleiotropic Effects on Human Adipose-Derived Stem Cells.
    Life (Basel). 2022;12.
    PubMed         Abstract available


    Med Lav

  44. CIOCAN C, Godono A, Franco N, La Vecchia C, et al
    Mortality from bladder cancer in dyestuff workers exposed to aromatic amines: A 73-year follow-up.
    Med Lav. 2022;113:e2022017.
    PubMed         Abstract available


    Mol Biol Rep

  45. FADALLAH M, Zahran MH, El-Assmy AM, Barakat NM, et al
    Omega-3 polyunsaturated fatty acids: a modified approach for chemo-prevention of bladder cancer in a rat model and molecular studies of antineoplastic mechanisms.
    Mol Biol Rep. 2022 Apr 25. pii: 10.1007/s11033-022-07445.
    PubMed         Abstract available


    Mol Carcinog

  46. GUO Q, Zhang T, Gong Y, Tao Y, et al
    Aldehyde dehydrogenase 6 family member A1 negatively regulates cell growth and to cisplatin sensitivity in bladder cancer.
    Mol Carcinog. 2022 Apr 26. doi: 10.1002/mc.23411.
    PubMed         Abstract available


    Mol Clin Oncol

  47. BURGESS EF, Livasy C, Trufan S, Zhu J, et al
    Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle-invasive bladder cancer.
    Mol Clin Oncol. 2022;16:102.
    PubMed         Abstract available


    Neurol Sci

  48. DE ROJAS LEAL C, Lage-Sanchez JM, Pinel-Rios J, Leon Plaza O, et al
    Paraneoplastic autoimmune autonomic ganglionopathy as the first symptom of bladder cancer: a case report and review of literature.
    Neurol Sci. 2022 Apr 28. pii: 10.1007/s10072-022-06075.
    PubMed         Abstract available


    Oncotarget

  49. ZLOWOCKA-PERLOWSKA E, van de Wetering T, Toloczko-Grabarek A, Scott RJ, et al
    Bladder cancer survival in patients with NOD2 or CDKN2A variants.
    Oncotarget. 2022;13:628-640.
    PubMed         Abstract available


    Oxid Med Cell Longev

  50. SUN X, Zhang Y, Chen Y, Xin S, et al
    In Silico Establishment and Validation of Novel Lipid Metabolism-Related Gene Signature in Bladder Cancer.
    Oxid Med Cell Longev. 2022;2022:3170950.
    PubMed         Abstract available


    Pathol Oncol Res

  51. EVANS H, O'Sullivan B, Hughes F, Charles K, et al
    PD-L1 Testing in Urothelial Carcinoma: Analysis of a Series of 1401 Cases Using Both the 22C3 and SP142 Assays.
    Pathol Oncol Res. 2022;28:1610260.
    PubMed         Abstract available


    Scand J Urol

  52. GONTERO P, Babjuk M
    Swedish national guidelines on urothelial cancer echo the EAU guidelines but with some regional dialect.
    Scand J Urol. 2022;56:147-148.
    PubMed        

  53. GAKIS G, Perner S, Stenzl A, Renninger M, et al
    The role of single-nucleotide polymorphisms of the 8q24 chromosome region in patients with concomitant bladder and prostate cancer.
    Scand J Urol. 2022;56:126-130.
    PubMed         Abstract available

  54. GUNNARSSON U
    Anorectal side-effects of radical cystectomy.
    Scand J Urol. 2022;56:162-163.
    PubMed        


    Sci Rep

  55. YERUKALA SATHIPATI S, Tsai MJ, Shukla SK, Ho SY, et al
    MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma.
    Sci Rep. 2022;12:4141.
    PubMed         Abstract available


    Semin Oncol

  56. LAUKHTINA E, Mori K, Mostafaei H, Merseburger AS, et al
    Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials.
    Semin Oncol. 2021;48:181-192.
    PubMed         Abstract available


    Urol Case Rep

  57. ERASLAN A, Ekenci BY, Dogan AE, Kaymak S, et al
    Parastomal skin metastasis in a patient with history of urinary bladder cancer.
    Urol Case Rep. 2022;43:102088.
    PubMed         Abstract available


    Urol Oncol

  58. EL-KARAMANY TM, Al-Adl AM, Hosny MM, A Eldeep H, et al
    Clinical utility of vesical imaging-reporting and data system (VI-RADS) in non-muscle invasive bladder cancer (NMIBC) patients candidate for en-bloc transurethral resection: A prospective study.
    Urol Oncol. 2022 Apr 21. pii: S1078-1439(22)00099.
    PubMed         Abstract available


    Urologia

  59. SYMEONIDIS EN, Baniotis P, Langas G, Stefanidis P, et al
    En bloc resection, is this the future of non-muscle invasive bladder cancer management? Presentation of our technique and brief review of the literature.
    Urologia. 2022 Apr 25:3915603221093739. doi: 10.1177/03915603221093739.
    PubMed         Abstract available


    Virchows Arch

  60. GARCZYK S, Degener S, Bischoff F, Schnitzler T, et al
    Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer.
    Virchows Arch. 2022 Apr 28. pii: 10.1007/s00428-022-03328.
    PubMed         Abstract available

  61. LOPEZ-BELTRAN A, Blanca A, Cimadamore A, Montironi R, et al
    T1 bladder carcinoma with variant histology: pathological features and clinical significance.
    Virchows Arch. 2022;480:989-998.
    PubMed         Abstract available


    World J Surg Oncol

  62. AL KHADER A, Fararjeh AFS, Kaddumi EG, Al-Saghbini M, et al
    Significance of fibulin-3 expression in bladder cancer: a tissue microarray-based immunohistochemical study.
    World J Surg Oncol. 2022;20:133.
    PubMed         Abstract available

  63. ZHANG Y, Zhou H, Tuo ZT, Wang J, et al
    Extraperitoneal laparoscopic radical cystectomy with intracorporeal neobladder: a comparison with transperitoneal approach.
    World J Surg Oncol. 2022;20:130.
    PubMed         Abstract available


    World J Urol

  64. RODLER S, Solyanik O, Ingenerf M, Fabritius M, et al
    Accuracy and prognostic value of radiological lymph node features in variant histologies of bladder cancer.
    World J Urol. 2022 Apr 23. pii: 10.1007/s00345-022-04010.
    PubMed         Abstract available

  65. FLEGAR L, Kraywinkel K, Zacharis A, Aksoy C, et al
    Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2019.
    World J Urol. 2022 Apr 29. pii: 10.1007/s00345-022-04017.
    PubMed         Abstract available


    Zhejiang Da Xue Xue Bao Yi Xue Ban

  66. CHEN Q, Cai L, Liang J
    Construction of prognosis model of bladder cancer based on transcriptome.
    Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021;50:1-9.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: